SCHEMBL2902807

SCHEMBL2902807

CCN(CC)C(c1ccc(-c2ccc(OC)cc2)cc1)c1c[nH]nc1-c1ccco1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.38
KDM4E B2RXH2 8/20 0.38
HPGD P15428 6/20 0.38
MAPT P10636 6/20 0.38
RAB9A P51151 4/20 0.38
MEN1 O00255 3/20 0.38
POLB P06746 3/20 0.38
KMT2A Q03164 3/20 0.38
BLM P54132 2/20 0.38
MCL1 Q07820 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
THRB P10828 1/20 0.38
ALOX12 P18054 1/20 0.38
PTPN7 P35236 1/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 4/20 0.36
TSHR P16473 3/20 0.36
GAA P10253 3/20 0.36
NPC1 O15118 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901803 0.88 PIK3R1 (0.35) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL2902674 0.84 PIK3R1 (0.38) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL5224724 0.80 KMT2A (0.38) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL2904631 0.77 MCHR1 (0.40) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL2901811 0.77 AKT1 (0.39) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL2905924 0.75 OPRD1 (0.40) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL2908995 0.75 BRAF (0.46) ALDH1A1KDM4EHPGDMAPTMEN1
SCHEMBL2902229 0.71 SMN1; SMN2 (0.47) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL2901677 0.71 MAPT (0.39) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL2904637 0.70 TP53 (0.33) ALDH1A1KDM4EHPGDMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885KDM4E 3489/4885HPGD 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.